Recursion Pharmaceuticals ( RXRX +1.91%) was in the headlines on Monday, and for the right reason. One of the biotech company ...

试验显示，REC-4881（每日一次4毫克）在12周治疗后实现了息肉总负担中位数减少43%，其中75%的可评估患者显示减少。值得注意的是，82%的可评估患者在停止治疗12周后仍保持持久减少，此时观察到基线中位数减少53%。

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) 股价周一上涨7%，此前该公司实验性药物REC-4881在家族性腺瘤性息肉病 (FAP)的2期临床试验中取得积极结果。FAP是一种罕见的遗传疾病，目前尚无获批疗法。

Getting in on the ground floor would be great, but only if there's massive upside ahead for the company.

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

By Sriparna Roy Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the ...

Recursion Pharmaceuticals (NASDAQ:RXRX) gained 7% on Monday after releasing encouraging Phase 2 results for REC-4881, its ...

Shares of Recursion Pharmaceuticals are trading higher Monday after the company reported positive data from an ongoing trial.

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...